Drugs / Sacubitril/Valsartan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05580510 | Feb → Jul 2023 | congenital heart disease, heart failure | Instituto Nacional de Cardiologia Ignacio Chavez | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/Valsartan | “Additionally, patients will receive Sacubitril/Valsartan, with the intention to titrate up to 49 mg/51 mg orally every 12 hours.” NCT05580510 ↗ |
| Action | Inhibit | “Sacubitril/valsartan rapidly and strongly reduced sNEP activity” PMID 30520545 ↗ Dec 2018 |